Sarepta To Share Initial Clinical Data On March 25th From siRNA Pipeline Phase 1/2 Dose Studies Of SRP-1001 For Facioscapulohumeral Muscular Dystrophy Type 1 And SRP-1003 For Myotonic Dystrophy

Benzinga Newsdesk www.benzinga.com Neutral 83.1%

Neg 0% Neu 83.1% Pos 0%

Comments

No comments yet. Be the first!